Where Are We Now? The Progression of Diversity, Equity and Inclusion in the Face of a Global Pandemic and Racial Reckoning
April 29, 2021 2:30 PM to 4:30 PM
It has been about one year since the WHO declared COVID-19 a global pandemic, and horrific acts of violence against black people shone the spotlight on the Black Lives Matter movement. These landmark events prompted law firms, companies, and other organizations to renew their focus on diversity, equity, and inclusion. But where are we now? How are firms, companies and other organizations continuing to address issues that have impeded the success and opportunities of diverse attorneys and creating a more inclusive workspace?
Join our panel of D&I leaders on April 29th beginning at 2:30pm (ET) to hear how far we have come and where we are heading. Break-out sessions will follow the presentations so that we can share our experiences and continue our journey towards a more inclusive and diverse profession.
DIIPL Project Team: DE&I Task Force
Moderator: Kim Gatling (Fox Rothschild)
Speakers: Phil Hampton (Polsinelli), Laura Acosta (Goodwin Procter), David Wallace (Johnson & Johnson) and Marilu Medina (Procter & Gamble)
Hosted by the Diversity in IP Law Committee
Speakers
-
Wallace, David
Johnson & Johnson | Group Leader, Health Technology Team
David Wallace is a member of the Johnson & Johnson Law Department, and Group Leader of the Health Technology Team. In his role as Group Leader, David’s primarily responsible for day-to-day activities regarding the patent aspects of the health technology initiatives across the Johnson & Johnson Family of Companies. -
Hampton, II, Philip G.
Polsinelli | Chief Diversity & Inclusion Officer and Senior Partner
Mr. Hampton, a multi-faceted IP law practitioner for more than 40 years, focuses on patent and trademark litigation, patent and trademark counseling, trademark prosecution, and licensing and merchandising agreements based on patents, trademarks, trade secrets, and copyrights as well as transactions related to the transfer of intellectual property pursuant to corporate acquisitions. -
Medina, Marilú
The Procter & Gamble Company | Director & Assistant General Counsel
Marilú Medina is Director & Assistant General Counsel at The Procter & Gamble Company, supporting its Global Privacy, Cybersecurity and Information Technology Law team. Her current work is focused on global employee data privacy compliance, including COVID-19 related privacy issues. -
Bullock Gatling, Kimberly
Fox Rothschild LLP | Partner and Chief Diversity & Inclusion Officer
Greensboro attorney Kimberly Bullock Gatling has built a reputation for her expertise in the field of intellectual property, licensing and litigation, while contributing to the growth of the legal profession in her role as partner and the first chief diversity & inclusion officer for one of the nation’s most prestigious law firms, Fox Rothschild LLP. -
Acosta, Laura
Goodwin | Managing Director, Diversity, Equity + Inclusion
Laura Acosta helps organizations unlock collaboration and innovation by disrupting the status quo. She is Managing Director of Diversity, Equity + Inclusion at Goodwin, a global 50 law firm with a history of working on groundbreaking matters and an increasingly focused approach to working with clients in the financial, private equity, real estate, technology and life sciences industries.
News
-
AIPLA Submits Comments on the World Intellectual Property Organization Riyadh Design Law Treaty
June 24, 2026
Alexandria, VA. June 11, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments on the World Intellectual Property Organization Riyadh Design Law Treaty. -
AIPLA Files Amicus Brief in Arbutus Biopharma Corp. v. Moderna, Inc.
June 22, 2026
Arlington, VA. June 5, 2026 – The American Intellectual Property Law Association (AIPLA) filed an amicus brief in Arbutus Biopharma Corp. v. Modernatx, Inc. -
Supreme Court Issues Unanimous Decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
June 4, 2026
On June 4, 2026, the Supreme Court issued a unanimous decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. While the Court reaffirmed existing law on pleading standards, it reversed the Federal Circuit’s decision that had focused on how relevant statements could be understood by medical providers as instructions to infringe. The amicus brief filed by AIPLA on March 27, 2026, advocated for affirmance and cautioned the Court not to change the patent infringement pleading standard or adopt any categorical exemption from inducement for a particular industry. -
AIPLA Views on H.R. 3269, the “ETHIC Act,” and H.R. 6485, the “Skinny Labels, Big Savings Act”
June 3, 2026
Arlington, VA. June 3, 2026 – The American Intellectual Property Law Association (AIPLA) submitted a letter to the House Judiciary Committee’s Subcommittee on Courts, Intellectual Property, Artificial Intelligence, and the Internet outlining its views on H.R. 3269, the “ETHIC Act,” and H.R. 6485, the “Skinny Labels, Big Savings Act.” -
AIPLA Submits Comments to the USPTO on 2026 Supplemental GUI Guidance
May 15, 2026
Arlington, VA. May 12, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments to the USPTO on its Supplemental Guidance for Examination of Design Patent Applications Related to Computer-Generated Interfaces and Icons, issued on March 13, 2026.
